EUCTR2019-001793-28-NL进行中（未招募）1 期
Adalimumab dose reduction aiming low serum concentration with control of disease activity (ADDORA-LOW) : a single blind, non-inferiority, randomised clinical trial - ADDORA-Low
Reade0 个研究点目标入组 89 人开始时间: 2019年11月5日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 89
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •rheumatoid arthritis patient, according to ACR 1987/2010 criteria;
- •treated for at least 28 weeks with adalimumab
- •adalimumab trough concentration >5mg/L
- •who has agreed to participate (written informed consent);
- •age 18 years or older.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 59
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •scheduled surgery during the follow-up of the study or other pre-planned reasons for treatment discontinuation
- •life expectancy shorter than follow-up period of the study;
- •no other disease that might flare if adalimumab is tapered like psoriasis, inflammatory bowel disease
研究者
相似试验
尚未招募
不适用
Adalimumab dose reduction aiming low serum concentration with control of disease activity (ADDORA-LOW) : a single blind, non-inferiority, randomised clinical trial10003816Rheumatoid arthritisNL-OMON55177Reade89
招募中
不适用
Adalimumab dose reduction aiming low serum concentration with control of disease activityRheumatoid arthritisNL-OMON24020Reade Rheumatology Research Institute89
终止
4 期
Dose Tapering Study of Adalimumab in PsoriasisPsoriasis VulgarisNCT04028713University Hospital, Ghent19
已完成
4 期
A Non-inferiority Study on Dose Reduction of Adalimumab in Psoriasis Patients Who Are OvertreatedPsoriasisNCT05683054University Hospital, Ghent19
已完成
4 期
Adalimumab Dose Reduction Aiming Low Serum Concentration With Control of Disease ActivityRheumatoid ArthritisNCT04222920Reade Rheumatology Research Institute78